4 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 4 |
Follow Abraxane: new trials by email Literature Review of Abraxane trials Research Report on Abraxane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed - NSCLC | Phase 3 | Terminated | EQRx International, Inc. | 8 | 2022-12-14 | 2024-05-02 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Relacorilant, 100 mg and 25 mg, Nab-paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Terminated | Corcept Therapeutics | 43 | 2020-06-30 | 2023-11-18 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss alpelisib, placebo, nab-paclitaxel - Triple Negative Breast Neoplasms | Phase 3 | Terminated | Novartis Pharmaceuticals | 137 | 2020-06-08 | 2026-09-10 |
| Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation - Pancreatic Cancer, Pancreatic Carcinoma Non-resectable | Phase 3 | Terminated | NewLink Genetics Corporation | 302 | 2013-05-01 | 2020-05-28 |
Pancreatic Neoplasms (2) · Triple Negative Breast Neoplasms (1)
Corcept Therapeutics (1) · EQRx International, Inc. (1) · NewLink Genetics Corporation (1) · Novartis Pharmaceuticals (1)
United States (4) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1) · China (1) · Colombia (1) · Croatia (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Israel (1) · Italy (1)
2019 (1)